Arvinas Inc.

Notes

Arvinas Inc. is a clinical-stage biopharmaceutical company that pioneered the development of PROTAC (proteolysis targeting chimera) technology for targeted protein degradation. Founded by Yale Professor Craig Crews, who invented the PROTAC approach, Arvinas is developing small molecule therapeutics that harness the body's natural protein disposal system to selectively eliminate disease-causing proteins.

Unlike traditional inhibitors that block protein function, PROTAC degraders recruit E3 ubiquitin ligases to tag target proteins for destruction by the proteasome. This approach can target proteins previously considered "undruggable" and may offer advantages over traditional small molecule inhibitors.

Arvinas is publicly traded on NASDAQ under the ticker symbol ARVN. The company has multiple clinical programs in oncology, including vepdegestrant (ARV-471) for estrogen receptor-positive breast cancer developed in partnership with Pfizer, and bavdegalutamide (ARV-110) for prostate cancer.

Team

• John Houston, Ph.D. - President & Chief Executive Officer
  • LinkedIn: linkedin.com/in/john-houston
• Craig Crews, Ph.D. - Founder & Chief Scientific Advisor
  • Yale University Professor, Inventor of PROTAC technology
• Ron Peck - Chief Financial Officer
• Ian Taylor, Ph.D. - Chief Scientific Officer

Additional Research Findings

• NASDAQ listed company (ARVN)
• Pioneer of PROTAC protein degradation technology
• Lead programs: vepdegestrant (breast cancer), bavdegalutamide (prostate cancer)
• Partnership with Pfizer for breast cancer program
• Investor: 5AM Ventures
• Founder Craig Crews invented PROTAC technology
• New Haven, Connecticut headquarters
• IPO in September 2018
• Founded 2013

Sources

• Arvinas Official Website
• Arvinas LinkedIn
• NASDAQ: ARVN
• 5AM Ventures Portfolio